JP2002541849A5 - - Google Patents

Download PDF

Info

Publication number
JP2002541849A5
JP2002541849A5 JP2000612459A JP2000612459A JP2002541849A5 JP 2002541849 A5 JP2002541849 A5 JP 2002541849A5 JP 2000612459 A JP2000612459 A JP 2000612459A JP 2000612459 A JP2000612459 A JP 2000612459A JP 2002541849 A5 JP2002541849 A5 JP 2002541849A5
Authority
JP
Japan
Prior art keywords
vegf
amino acid
vegf variant
acid substitution
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000612459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002541849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/009483 external-priority patent/WO2000063380A1/en
Publication of JP2002541849A publication Critical patent/JP2002541849A/ja
Publication of JP2002541849A5 publication Critical patent/JP2002541849A5/ja
Pending legal-status Critical Current

Links

JP2000612459A 1999-04-16 2000-04-10 血管内皮細胞増殖因子変異体とその用途 Pending JP2002541849A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12978899P 1999-04-16 1999-04-16
US60/129,788 1999-04-16
US18423500P 2000-02-23 2000-02-23
US60/184,235 2000-02-23
PCT/US2000/009483 WO2000063380A1 (en) 1999-04-16 2000-04-10 Vascular endothelial cell growth factor variants and uses thereof

Publications (2)

Publication Number Publication Date
JP2002541849A JP2002541849A (ja) 2002-12-10
JP2002541849A5 true JP2002541849A5 (cg-RX-API-DMAC7.html) 2007-06-14

Family

ID=26827914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000612459A Pending JP2002541849A (ja) 1999-04-16 2000-04-10 血管内皮細胞増殖因子変異体とその用途

Country Status (15)

Country Link
US (1) US20060063203A1 (cg-RX-API-DMAC7.html)
EP (2) EP1655368B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002541849A (cg-RX-API-DMAC7.html)
KR (1) KR100634926B1 (cg-RX-API-DMAC7.html)
CN (1) CN1328376C (cg-RX-API-DMAC7.html)
AT (2) ATE329024T1 (cg-RX-API-DMAC7.html)
AU (1) AU771042B2 (cg-RX-API-DMAC7.html)
CA (1) CA2370246C (cg-RX-API-DMAC7.html)
DE (2) DE60041367D1 (cg-RX-API-DMAC7.html)
ES (2) ES2265931T3 (cg-RX-API-DMAC7.html)
HU (1) HU228898B1 (cg-RX-API-DMAC7.html)
IL (2) IL145675A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01010469A (cg-RX-API-DMAC7.html)
NZ (1) NZ514488A (cg-RX-API-DMAC7.html)
WO (1) WO2000063380A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド eNOS活性の調節とその治療的使用
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
JP2005519980A (ja) 2002-03-01 2005-07-07 ブラッコ インターナショナル ビー.ヴイ. 治療および診断用途の多価構成物
SI2301587T1 (sl) * 2002-03-01 2014-11-28 Dyax Corp. KDR in VEGF/KDR vezavni peptidi in njihova uporaba pri diagnozi
IL165392A0 (en) 2002-06-05 2006-01-15 Genentech Inc Compositions and methods for liver growth and liver protection
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
HUE029170T2 (en) 2004-07-20 2017-03-28 Genentech Inc Preparations and methods for the use of angiopoietin-like protein 4
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
WO2007109183A2 (en) * 2006-03-20 2007-09-27 Novartis Ag Mutations and polymorphisms of fms-related tyrosine kinase 1
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169292A (en) * 1875-10-26 Improvement in butter-packages
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
CN1185159A (zh) * 1995-06-06 1998-06-17 人体基因组科学有限公司 人血管内皮生长因子3
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids

Similar Documents

Publication Publication Date Title
Lim et al. Double-layered adhesive microneedle bandage based on biofunctionalized mussel protein for cardiac tissue regeneration
Hansson et al. Regenerating endothelial cells express insulin-like growth factor-I immunoreactivity after arterial injury
Kim et al. The enhancement of mature vessel formation and cardiac function in infarcted hearts using dual growth factor delivery with self-assembling peptides
DE60219611T2 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
CN105451554B (zh) 用于治疗血管紧张素相关疾病的方法、化合物和组合物
AU2019314383B2 (en) Engineered hemichannels, engineered vesicles, and uses thereof
CN102369026B (zh) Pcl/pga止血泡沫
WO2002064157A3 (en) Localized myocardial injection method for treating ischemic myocardium
WO2002089856A8 (en) Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery
CA2404163A1 (en) Production of recombinant blood clotting factors in human cell lines
JPH03500782A (ja) 創傷の治癒
EP2428215A1 (en) An angiogenesis inducing agent comprising recombinant gelatin
Yu et al. An engineered VEGF‐activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced‐age mice
CN115040695B (zh) 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用
CN108753730A (zh) 一种ntf4基因修饰的脐带间充质干细胞及其构建方法和应用
Hoppenbrouwers et al. Fibrin improves skin wound perfusion in a diabetic rat model
JP2002541849A (ja) 血管内皮細胞増殖因子変異体とその用途
Sugimoto et al. Functional property of von Willebrand factor under flowing blood
HK1048593A1 (zh) 用於通过体内基因输送治疗心血管疾病的技术和组合物
WO2003059436A3 (en) Compositions and methods for promoting myocardial and peripheral angiogenesis
JP2002539827A5 (cg-RX-API-DMAC7.html)
US7084117B2 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
Coronel et al. Cardiac expression of skeletal muscle sodium channels increases longitudinal conduction velocity in the canine 1-week myocardial infarction
CA2161669A1 (en) Use of platelet-derived growth factor to improve collateral circulation
JP2003500341A5 (cg-RX-API-DMAC7.html)